drugset / Trial / NCT04370236
INB03 for the Treatment of Pulmonary Complications From COVID-19
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
Timeline
- Start
- 2020-10-21
- Primary completion
- 2021-10-13
- Completion
- 2021-11-18
Outcome
Outcome not reported
Stopped: “Futility”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEGIPANERMIN | Protein / enzyme biologic | 1 mg/kg | Subcutaneous |